Innate Pharma
Innate Pharma halts lymphomas trials after patient death, but key study continues
Anika Sharma
Innate Pharma has encountered a safety issue in its lymphoma program, resulting in the FDA imposing a partial clinical hold ...
SAR’579/IPH6101 Granted FDA Fast Track Designation for Hematological Malignancies
SG Tylor
Source: Innate Pharma On June 6, 2023, the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ...
Innate Pharma Showcases Breakthrough Tetra-Specific ANKET NK Cell Engager IPH6501 at the EHA 2023 Congress
SG Tylor
Source: Innate Pharma On June 10, 2023, Innate Pharma, a biopharmaceutical company, highlights the latest preclinical findings on IPH6501, a ...
